Co-Diagnostics Inc
NASDAQ:CODX
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.01
1.75
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one CODX stock under the Base Case scenario is 0.42 USD. Compared to the current market price of 1.22 USD, Co-Diagnostics Inc is Overvalued by 65%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Co-Diagnostics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for CODX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Co-Diagnostics Inc
Balance Sheet Decomposition
Co-Diagnostics Inc
Current Assets | 48.2m |
Cash & Short-Term Investments | 44.9m |
Receivables | 551.5k |
Other Current Assets | 2.8m |
Non-Current Assets | 32.5m |
Long-Term Investments | 627.9k |
PP&E | 5.6m |
Intangibles | 26.3m |
Other Non-Current Assets | 10 |
Current Liabilities | 5.3m |
Accounts Payable | 1.9m |
Accrued Liabilities | 2.4m |
Other Current Liabilities | 1.1m |
Non-Current Liabilities | 3m |
Other Non-Current Liabilities | 3m |
Earnings Waterfall
Co-Diagnostics Inc
Revenue
|
9.1m
USD
|
Cost of Revenue
|
-3.7m
USD
|
Gross Profit
|
5.5m
USD
|
Operating Expenses
|
-44.2m
USD
|
Operating Income
|
-38.7m
USD
|
Other Expenses
|
1.1m
USD
|
Net Income
|
-37.6m
USD
|
Free Cash Flow Analysis
Co-Diagnostics Inc
USD | |
Free Cash Flow | USD |
In Q2 2024, Co-Diagnostics achieved a remarkable revenue increase to $2.7 million, up from $0.2 million year-over-year, primarily driven by $2.5 million in grant revenue. Despite a net loss of $7.6 million, reduced operating expenses reflect better cost management. The firm is progressing towards a commercial launch of its Co-Dx PCR platform, having submitted a pivotal 510(k) application to the FDA. The market for tuberculosis testing is projected to reach over $3.6 billion in four years, positioning Co-Diagnostics for significant growth as it targets both domestic and international markets.
What is Earnings Call?
CODX Profitability Score
Profitability Due Diligence
Co-Diagnostics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Co-Diagnostics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
CODX Solvency Score
Solvency Due Diligence
Co-Diagnostics Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Score
Co-Diagnostics Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CODX Price Targets Summary
Co-Diagnostics Inc
According to Wall Street analysts, the average 1-year price target for CODX is 1.53 USD with a low forecast of 1.52 USD and a high forecast of 1.58 USD.
Dividends
Current shareholder yield for CODX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
CODX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company is headquartered in Salt Lake City, Utah and currently employs 101 full-time employees. The company went IPO on 2017-07-12. The firm is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. The company also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The firm uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.
Contact
IPO
Employees
Officers
The intrinsic value of one CODX stock under the Base Case scenario is 0.42 USD.
Compared to the current market price of 1.22 USD, Co-Diagnostics Inc is Overvalued by 65%.